Merlin Biotech, Inc.
Biotechnology spinout using clinically validated mRNA platforms to develop therapeutics and vaccines for unmet medical needs, with a lead program encoding USP6 for cancer immunotherapy. The organization pursues preclinical and IND-enabling studies, clinical development planning, and collaborations with translational research centers.
Industries
N/A
Nr. of Employees
small (1-50)
Merlin Biotech, Inc.
Products
Lead mRNA immunotherapy candidate encoding USP6 (lead program)
An mRNA therapeutic candidate encoding the naturally occurring protein USP6 designed to activate multiple immunostimulatory pathways when delivered into tumors; being developed for adult solid tumors and Ewing sarcoma.
Lead mRNA immunotherapy candidate encoding USP6 (lead program)
An mRNA therapeutic candidate encoding the naturally occurring protein USP6 designed to activate multiple immunostimulatory pathways when delivered into tumors; being developed for adult solid tumors and Ewing sarcoma.
Services
Planning and execution of IND-enabling preclinical studies to support regulatory submissions and early clinical entry.
Protocol and clinical development planning for early-phase trials including Phase I and Phase II planning.
Planning and execution of IND-enabling preclinical studies to support regulatory submissions and early clinical entry.
Protocol and clinical development planning for early-phase trials including Phase I and Phase II planning.
Expertise Areas
- mRNA therapeutics development
- Cancer immunotherapy
- Vaccine development
- Clinical study design and execution
Key Technologies
- mRNA design and in vitro transcription
- Lipid nanoparticle delivery
- Intratumoral mRNA delivery
- mRNA-encoded protein expression
News & Updates
Company CEO presented technology overview and strategic plan at the BioFuture conference; slides and deck were shared.
Announcement of an investment allocation where $100,000 was used to purchase shares in the company to support development of cancer treatments including therapies for Ewing's sarcoma.
Presentation of the lead program (USP6-encoding mRNA) at the Biotech Showcase; company described plans for IND-enabling studies and Phase I/II clinical development.
Company won the Startup Springboard competition at Biotech Week Boston, recognition for early-stage innovation and strategy.
Announcement of company spinout leveraging mRNA technology for therapeutics and vaccines, supported by the Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center.
Selected winner of a competition at Biotech Week Boston among 11 startup companies, judged on innovation and clinical development strategy.
Company CEO presented technology overview and strategic plan at the BioFuture conference; slides and deck were shared.
Announcement of an investment allocation where $100,000 was used to purchase shares in the company to support development of cancer treatments including therapies for Ewing's sarcoma.
Presentation of the lead program (USP6-encoding mRNA) at the Biotech Showcase; company described plans for IND-enabling studies and Phase I/II clinical development.
Company won the Startup Springboard competition at Biotech Week Boston, recognition for early-stage innovation and strategy.
Announcement of company spinout leveraging mRNA technology for therapeutics and vaccines, supported by the Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center.
Selected winner of a competition at Biotech Week Boston among 11 startup companies, judged on innovation and clinical development strategy.